Aller au contenu principal
2023 article

Renal function is a major predictor of circulating acyl-CoA-binding protein/diazepam-binding inhibitor

0Citations signalées, ce qui n’est pas une note de qualité
5Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : de, us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Objective Acyl-CoA-binding protein (ACBP)/diazepam-binding inhibitor has recently been introduced as an endocrine factor affecting food intake and lipid metabolism. ACBP is dysregulated in catabolic/malnutrition states like sepsis or systemic inflammation. However, regulation of ACBP has not been investigated in human and murine chronic kidney disease (CKD) and kidney failure (KF), so far. Design/Methods Serum ACBP levels were quantified by enzyme-linked immunosorbent assay (ELISA) in 60 subjects with KF on chronic hemodialysis compared to 60 subjects with an estimated glomerular filtration rate > 50 ml/min/1.73m 2 in a cross-sectional cohort. Furthermore, mRNA expression of mACBP was determined in two CKD mouse models compared to two different groups of non-CKD control mice. Moreover, mRNA expression of mACBP was investigated in cultured, differentiated mouse brown and white adipocytes after treatment with the uremic toxin indoxyl sulfate. Results Median [interquartile range] serum ACBP was significantly, almost 20-fold, increased in KF (514.0 [339.3] µg/l) compared to subjects with a preserved renal function (26.1 [39.1] µg/l) (p<0.001). Renal function was the most important, inverse predictor of circulating ACBP in multivariate analysis (standardized β=-0.839; p<0.001). Increased ACBP levels were not caused by augmented mACBP mRNA expression in different tissues of CKD mice in vivo or in indoxyl sulfate-treated adipocytes in vitro. Conclusions Circulating ACBP inversely associates with renal function, most likely through renal retention of the cytokine. Future studies need to investigate ACBP physiology in malnutrition-related disease states, such as CKD. Markers of renal function need to be reported in future studies on ACBP. Publication History Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Renal function is a major predictor of circulating acyl-CoA-binding protein/diazepam-binding inhibitor
Date Crossref
01/04/2023
Éditeur
Georg Thieme Verlag KG
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Metabolism and Genetic DisordersDiet and metabolism studiesPeroxisome Proliferator-Activated Receptors

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.